JPMorgan Chase & Co. Lowers Zoetis (NYSE:ZTS) Price Target to $115.00

Zoetis (NYSE:ZTS) had its price target decreased by equities research analysts at JPMorgan Chase & Co. from $130.00 to $115.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 58.26% from the company’s previous close.

Several other analysts have also recently issued reports on the stock. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Citigroup reduced their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, Morgan Stanley set a $85.00 price target on Zoetis in a research note on Friday. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $115.92.

Zoetis Stock Down 6.0%

ZTS stock traded down $4.60 during midday trading on Friday, hitting $72.67. 7,805,101 shares of the company’s stock were exchanged, compared to its average volume of 5,760,366. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis has a 12-month low of $71.47 and a 12-month high of $160.48. The firm has a 50 day moving average price of $76.76 and a 200-day moving average price of $100.95. The stock has a market capitalization of $30.46 billion, a price-to-earnings ratio of 12.03, a price-to-earnings-growth ratio of 1.16 and a beta of 0.74.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the prior year, the company posted $1.76 EPS. Zoetis’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts anticipate that Zoetis will post 6.87 EPS for the current year.

Insider Transactions at Zoetis

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by insiders.

Institutional Trading of Zoetis

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. RFG Advisory LLC increased its stake in Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares in the last quarter. Quest 10 Wealth Builders Inc. lifted its stake in Zoetis by 4.7% in the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after buying an additional 86 shares in the last quarter. Financial Engines Advisors L.L.C. boosted its holdings in shares of Zoetis by 4.4% in the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after buying an additional 87 shares during the period. Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its holdings in shares of Zoetis by 20.9% in the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 520 shares of the company’s stock valued at $65,000 after buying an additional 90 shares during the period. Finally, Physician Wealth Advisors Inc. increased its position in shares of Zoetis by 17.4% during the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after acquiring an additional 91 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Q2 earnings beat estimates: Zoetis reported adjusted earnings of $1.87 per share, ahead of the approximately $1.85 consensus and up from $1.76 a year earlier. However, revenue of $2.47 billion slightly missed expectations and was essentially flat year over year. Zoetis Surpasses Q2 Earnings Estimates
• Neutral Sentiment: Finance leadership change: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with reports also describing an expanded chief operating officer role. The change could support execution, but it is unlikely to offset the near-term demand concerns. Zoetis Appoints Jay Saccaro
• Negative Sentiment: 2026 guidance was cut materially: Zoetis now expects adjusted earnings per share of $6.15-$6.25, below the roughly $6.87 analyst consensus, and revenue of $9.1-$9.3 billion versus estimates near $9.8 billion. The reduced forecast signals that management expects softer growth and lower profitability for the year. Zoetis Q2 Earnings Beat, Revenue Miss, 2026 View Cut
• Negative Sentiment: Companion Animal weakness deepened: Management cited lower veterinary traffic, greater customer price sensitivity and increased competition. Zoetis plans additional promotions to defend market share, which may pressure pricing and margins. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.